---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-012635"
form_type: "8-K"
ticker: "HRMY"
cik: "0001802665"
company_name: "Harmony Biosciences Holdings, Inc."
filed_at: "2023-08-01T23:59:59+00:00"
generated_at: "2026-06-12T18:46:35.422371+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Harmony Biosciences Q2 net revenue $134.2M, up 25% YoY; board approves $125M buyback

## Summary
- Q2 net revenue $134.2M vs $107.0M YoY (+25%); GAAP net income $34.3M ($0.56 diluted EPS).
- Non-GAAP adjusted net income $45.9M ($0.76 diluted EPS) vs $34.7M ($0.57) YoY.
- Average patients on WAKIX ~5,450, up ~350 sequentially; exited Q2 with ~5,600 patients.
- Phase 3 IH INTUNE study fully enrolled; topline data expected Q4 2023. PWS Phase 3 study to initiate Q4 2023.
- Board authorized $125M share repurchase program with no expiration date.

## SEC filing metadata
- accession: 0001558370-23-012635
- form_type: 8-K
- ticker: HRMY
- cik: 0001802665
- company_name: Harmony Biosciences Holdings, Inc.
- filed_at: 2023-08-01T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1802665/000155837023012635/0001558370-23-012635-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1802665/000155837023012635/hrmy-20230801x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-012635
- JSON: https://secwatch.observer/filing/0001558370-23-012635.json
- Plain text: https://secwatch.observer/filing/0001558370-23-012635.txt

## Key facts
- Earnings Releases
  Harmony Biosciences Holdings, Inc. reported quarter ended June 30, 2023 results: net income 34.3 million, EPS 0.56.
  - Period: quarter ended June 30, 2023
  - Net income: 34.3 million
  - EPS: 0.56
  - Result: reported results
  source text: Net product revenues for the quarter ended June 30, 2023 were $134.2 million, compared to $107.0 million for the same period in 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1802665/000155837023012635/0001558370-23-012635-index.htm
- Earnings Releases
  Harmony Biosciences Holdings, Inc. reported quarter ended June 30, 2023 results: net income 34.3 million, EPS 0.56.
  - Period: quarter ended June 30, 2023
  - Net income: 34.3 million
  - EPS: 0.56
  - Result: reported results
  source text: GAAP net income for the quarter ended June 30, 2023, was $34.3 million, or $0.56 earnings per diluted share, compared to GAAP net income of $23.5 million, or $0.39 earnings per diluted share, for the same period in 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1802665/000155837023012635/0001558370-23-012635-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.